Federal Health Agency Allocates Funding for Research on Psychedelic Reform Impacts
A notice of special interest issued by the National Institute on Drug Abuse (NIDA) highlights the urgent need for research into the evolving laws surrounding psychedelics in cities and states across the United States. The agency is particularly interested in exploring the effects of regulated access to substances like psilocybin, as part of the growing psychedelic reform movement. NIDA aims to fund research projects that investigate the potential impact of these policy changes on consumption trends, public health outcomes, and other relevant factors. The call for research comes in the wake of various jurisdictions adopting different approaches to psychedelic reform, including legalization, decriminalization, and reduced penalties.
One notable example is Oregon, where voters approved a ballot measure in 2020 legalizing psilocybin services. Similarly, Colorado has taken steps to legalize a wider range of psychedelics and establish “healing centers” for their administration. As these state-level policy developments continue to unfold and more cities enact local decriminalization measures, NIDA recognizes the need to understand the implications on various aspects of society.
NIDA’s research initiatives will cover a range of critical areas. These include examining the relationship between decriminalization or legalization of psychedelic and dissociative drugs and their rates of use among different populations. Additionally, researchers will explore the impact of psychedelic and dissociative drug use on public health outcomes, harms, and abuse potential. The agency also aims to investigate the effects of different regulatory frameworks, such as taxation, labeling, and retail sales, on health outcomes and incarceration rates, particularly among vulnerable populations.
Another area of focus will be studying the placement of retailers and centers that provide psychedelic and dissociative drugs and their impact on surrounding communities. Furthermore, researchers will compare psychedelic and dissociative drug use and abuse potential to other substances like alcohol, tobacco, and cannabis. Preventing misuse and diversion of psychedelics, as well as assessing the long-term impacts of supervised use within centers on seeking and misusing other substances, will also be explored. Lastly, the agency will assess public perceptions of harm associated with psychedelic and dissociative drugs following policy enactments and implementation.
It is worth noting that NIDA announced earlier this year its intention to provide $1.5 million in funding to support research into how psychedelics could be utilized for treating drug addiction. The agency’s director, Nora Volkow, emphasized the significant potential of psychedelics as therapeutic treatments for specific mental health conditions during a Senate committee hearing. She expressed the growing interest among researchers in this field and acknowledged the challenges posed by federal prohibition in conducting further studies.
Federal lawmakers have also been actively engaged in promoting research into the therapeutic potential of psychedelics. Last year, Senators Brian Schatz (D-HI) and Cory Booker (D-NJ) pushed for updates on psychedelic research, citing the hindrances posed by federal prohibition. Responding to the inquiry, NIDA acknowledged the additional regulatory hurdles researchers face due to prohibition. Volkow, in particular, highlighted the need for prioritizing psychedelics research as more people become aware of their therapeutic potential.
In a bipartisan effort, lawmakers recently introduced a bill to create a $75 million federal grant program specifically focused on researching the therapeutic potential of psychedelics for certain health conditions among active duty military service members. The legislation received support from both Republican lawmakers and military veterans, with personal testimonies highlighting the positive impact of psychedelic-assisted treatment on their lives.
Additionally, another bill was filed to streamline the federal rescheduling process for “breakthrough therapies” like psilocybin and MDMA, aiming to facilitate research and drug development. This bipartisan effort, spearheaded by Booker, Senator Rand Paul (R-KY), and Representative Nancy Mace (R-SC), coincided with the re-launch of a congressional caucus dedicated to promoting research into the therapeutic potential of entheogenic substances.
As the psychedelic reform movement gains momentum across the country, NIDA’s commitment to funding research on the impacts of these policy changes is a significant step toward understanding the potential benefits and risks associated with regulated access to psychedelics. By investigating consumption trends, public health outcomes, and the experiences of vulnerable populations, researchers can provide valuable insights that inform future policies and interventions in this evolving field.
